Evotec SE Key Executives
This section highlights Evotec SE's key executives, including their titles and compensation details.
Find Contacts at Evotec SE
(Showing 0 of )
Evotec SE Earnings
This section highlights Evotec SE's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-04-17 | $0.02 | $-0.12 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $-0.08 | $-0.12 |
| Read Transcript | Q2 | 2024 | 2024-08-14 | $-0.09 | $-0.29 |
| Read Transcript | Q1 | 2024 | 2024-05-22 | $-0.03 | $-0.05 |
| Read Transcript | Q4 | 2023 | 2024-04-24 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-11-11 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-29 | $-0.04 | $-0.04 |
| Read Transcript | Q1 | 2023 | 2023-04-27 | N/A | N/A |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
$4.25
Stock Price
$3.02B
Market Cap
4.83K
Employees
Hamburg, None
Location
Financial Statements
Access annual & quarterly financial statements for Evotec SE, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $796.97M | $781.43M | $751.45M | $618.03M | $500.92M |
| Cost of Revenue | $682.09M | $606.38M | $577.38M | $466.49M | $375.18M |
| Gross Profit | $114.88M | $175.05M | $174.06M | $151.54M | $125.74M |
| Gross Profit Ratio | 14.41% | 22.40% | 23.16% | 24.52% | 25.10% |
| Research and Development Expenses | $50.86M | $68.53M | $76.64M | $72.20M | $63.95M |
| General and Administrative Expenses | $170.72M | $152.74M | $142.70M | $96.02M | $77.24M |
| Selling and Marketing Expenses | $17.48M | $16.87M | $13.49M | $9.42M | $9.50M |
| Selling General and Administrative Expenses | $188.20M | $169.61M | $156.19M | $105.44M | $77.24M |
| Other Expenses | $18.34M | $-15.58M | $-79.62M | $-67.78M | $-67.21M |
| Operating Expenses | $257.40M | $222.56M | $153.22M | $109.86M | $73.98M |
| Cost and Expenses | $939.49M | $828.93M | $730.60M | $576.36M | $449.16M |
| Interest Income | $2.44M | $9.26M | $8.34M | $2.27M | $1.34M |
| Interest Expense | $11.70M | $11.74M | $13.15M | $9.25M | $8.46M |
| Depreciation and Amortization | $101.62M | $92.98M | $81.66M | $67.61M | $56.06M |
| EBITDA | $-80.66M | $24.12M | $-86.08M | $298.41M | $75.50M |
| EBITDA Ratio | -10.12% | 3.09% | -11.46% | 48.28% | 15.07% |
| Operating Income | $-142.52M | $-47.51M | $12.49M | $27.32M | $48.52M |
| Operating Income Ratio | -17.88% | -6.08% | 1.66% | 4.42% | 9.69% |
| Total Other Income Expenses Net | $-51.45M | $-33.09M | $-174.81M | $195.98M | $-22.72M |
| Income Before Tax | $-193.98M | $-80.59M | $-153.96M | $236.98M | $25.81M |
| Income Before Tax Ratio | -24.34% | -10.31% | -20.49% | 38.34% | 5.15% |
| Income Tax Expense | $2.10M | $3.32M | $21.70M | $21.47M | $19.55M |
| Net Income | $-196.08M | $-83.91M | $-175.66M | $215.51M | $6.28M |
| Net Income Ratio | -24.60% | -10.74% | -23.38% | 34.87% | 1.25% |
| EPS | $-0.28 | $-0.12 | $-0.50 | $0.65 | $0.02 |
| EPS Diluted | $-0.28 | $-0.12 | $-0.50 | $0.65 | $0.02 |
| Weighted Average Shares Outstanding | 709.39M | 707.67M | 353.35M | 332.81M | 307.50M |
| Weighted Average Shares Outstanding Diluted | 709.39M | 707.67M | 353.41M | 332.81M | 307.50M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $221.23M | $184.89M | $182.12M | $208.73M | $201.31M | $196.28M | $170.28M | $213.56M | $240.69M | $173.88M | $172.20M | $164.67M | $187.07M | $159.66M | $138.22M | $133.09M | $140.51M | $129.43M | $111.59M | $119.40M |
| Cost of Revenue | $175.13M | $166.61M | $166.38M | $173.97M | $163.65M | $158.45M | $123.96M | $160.32M | $158.23M | $145.46M | $141.31M | $132.38M | $135.00M | $116.49M | $112.59M | $102.41M | $103.96M | $93.30M | $91.79M | $86.13M |
| Gross Profit | $46.10M | $18.28M | $15.74M | $34.76M | $37.67M | $37.82M | $46.32M | $53.24M | $82.46M | $28.42M | $30.89M | $32.29M | $52.07M | $43.17M | $25.62M | $30.68M | $36.55M | $36.12M | $19.79M | $33.27M |
| Gross Profit Ratio | 20.84% | 9.89% | 8.64% | 16.65% | 18.71% | 19.27% | 27.20% | 24.93% | 34.26% | 16.34% | 17.94% | 19.61% | 27.84% | 27.04% | 18.54% | 23.05% | 26.02% | 27.91% | 17.74% | 27.87% |
| Research and Development Expenses | $9.73M | $11.87M | $13.01M | $16.24M | $20.16M | $17.50M | $12.38M | $18.49M | $21.32M | $18.48M | $18.73M | $18.11M | $18.73M | $18.04M | $16.97M | $18.46M | $17.87M | $16.28M | $14.74M | $15.06M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $31.57M | $24.99M | $24.65M | $25.19M | $21.19M | $19.11M | $21.60M | $19.28M | $17.25M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $9.42M | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $49.90M | $46.39M | $45.97M | $45.94M | $42.13M | $39.29M | $45.61M | $42.58M | $46.33M | $42.46M | $35.83M | $31.57M | $34.41M | $24.65M | $25.19M | $21.19M | $19.11M | $21.60M | $19.28M | $17.25M |
| Other Expenses | $-20.32M | $-13.49M | $61.37M | $1.89M | $-3.18M | $4.40M | $10.59M | $-12.53M | $-22.88M | $-19.00M | $-19.89M | $-17.85M | $-18.00K | $17.00K | $-30.00K | $-30.00K | $286.00K | $-196.00K | $170.00K | $-8.00K |
| Operating Expenses | $39.31M | $44.78M | $58.98M | $62.18M | $62.29M | $50.00M | $82.61M | $40.72M | $44.77M | $41.95M | $34.66M | $31.83M | $37.13M | $25.43M | $23.40M | $23.90M | $20.07M | $19.75M | $16.97M | $17.18M |
| Cost and Expenses | $214.44M | $211.38M | $225.36M | $236.15M | $225.94M | $208.45M | $206.57M | $201.04M | $203.00M | $187.41M | $175.97M | $164.21M | $172.13M | $141.92M | $136.00M | $126.31M | $124.03M | $113.06M | $108.77M | $103.31M |
| Interest Income | $-367.00K | $917.00K | $467.00K | $1.42M | $1.10M | $2.48M | $2.83M | $2.85M | $3.31M | $3.00M | $1.23M | $789.00K | $594.00K | $637.00K | $539.00K | $502.00K | $- | $- | $928.00K | $1.08M |
| Interest Expense | $4.42M | $1.87M | $2.74M | $2.67M | $3.18M | $3.52M | $2.54M | $2.50M | $2.28M | $3.06M | $3.67M | $4.15M | $3.02M | $1.94M | $1.99M | $2.31M | $- | $1.35M | $2.64M | $2.75M |
| Depreciation and Amortization | $- | $- | $1.45M | $17.77M | $17.77M | $22.38M | $22.38M | $22.38M | $15.74M | $12.52M | $18.86M | $12.52M | $12.52M | $9.55M | $14.54M | $9.55M | $9.55M | $8.10M | $14.18M | $8.10M |
| EBITDA | $-11.45M | $-45.01M | $-103.17M | $-15.95M | $-11.70M | $-9.75M | $-17.90M | $-1.22M | $-10.52M | $-36.70M | $-6.50M | $-60.48M | $-11.94M | $142.33M | $65.88M | $56.75M | $11.02M | $8.87M | $240.00K | $21.62M |
| EBITDA Ratio | -5.18% | -24.34% | -56.65% | -7.64% | -5.81% | -4.97% | -10.51% | -0.57% | -4.37% | -21.10% | -3.78% | -36.73% | -6.38% | 89.14% | 47.66% | 42.64% | 7.84% | 6.86% | 0.22% | 18.11% |
| Operating Income | $6.78M | $-26.49M | $-104.61M | $-27.42M | $-24.62M | $-12.19M | $-36.29M | $12.52M | $37.69M | $-13.53M | $-3.77M | $125.36M | $14.94M | $17.74M | $1.54M | $6.78M | $13.24M | $16.37M | $2.82M | $16.09M |
| Operating Income Ratio | 3.07% | -14.33% | -57.44% | -13.14% | -12.23% | -6.21% | -21.31% | 5.86% | 15.66% | -7.78% | -2.19% | 76.13% | 7.99% | 11.11% | 1.11% | 5.09% | 9.42% | 12.65% | 2.53% | 13.48% |
| Total Other Income Expenses Net | $-22.65M | $-20.38M | $151.00K | $638.00K | $-12.48M | $-17.73M | $15.85M | $-18.73M | $-55.21M | $-29.84M | $-20.57M | $-69.20M | $-32.78M | $122.65M | $58.45M | $47.66M | $-6.78M | $-8.85M | $-9.87M | $17.91M |
| Income Before Tax | $-15.87M | $-46.87M | $-104.45M | $-25.73M | $-14.88M | $-29.92M | $-20.44M | $-6.21M | $-17.52M | $-43.36M | $-24.34M | $-68.73M | $-17.84M | $140.39M | $59.98M | $54.44M | $6.46M | $7.52M | $-7.05M | $18.87M |
| Income Before Tax Ratio | -7.17% | -25.35% | -57.35% | -12.33% | -7.39% | -15.24% | -12.00% | -2.91% | -7.28% | -24.94% | -14.13% | -41.74% | -9.53% | 87.93% | 43.40% | 40.91% | 4.60% | 5.81% | -6.31% | 15.80% |
| Income Tax Expense | $24.97M | $-7.24M | $-9.52M | $-6.11M | $-7.89M | $9.04M | $-5.51M | $7.68M | $9.68M | $3.91M | $3.60M | $4.51M | $13.64M | $6.12M | $-30.00K | $1.74M | $6.06M | $8.93M | $2.77M | $1.79M |
| Net Income | $-40.84M | $-39.63M | $-94.93M | $-20.67M | $-16.13M | $-38.95M | $-14.93M | $-13.90M | $-27.20M | $-47.27M | $-27.94M | $-73.24M | $-31.48M | $134.27M | $60.02M | $52.70M | $403.00K | $-1.41M | $-9.82M | $17.08M |
| Net Income Ratio | -18.46% | -21.44% | -52.13% | -9.90% | -8.01% | -19.85% | -8.77% | -6.51% | -11.30% | -27.19% | -16.22% | -44.48% | -16.83% | 84.10% | 43.42% | 39.60% | 0.29% | -1.09% | -8.80% | 14.30% |
| EPS | $-0.06 | $-0.06 | $-0.27 | $-0.06 | $-0.05 | $-0.11 | $-0.04 | $-0.04 | $-0.08 | $-0.14 | $-0.08 | $-0.21 | $-0.09 | $0.41 | $0.19 | $0.16 | $0.00 | $0.00 | $-0.03 | $0.06 |
| EPS Diluted | $-0.06 | $-0.05 | $-0.27 | $-0.06 | $-0.05 | $-0.11 | $-0.04 | $-0.04 | $-0.08 | $-0.14 | $-0.08 | $-0.21 | $-0.09 | $0.41 | $0.19 | $0.16 | $0.00 | $0.00 | $-0.03 | $0.06 |
| Weighted Average Shares Outstanding | 709.39M | 709.39M | 354.61M | 354.60M | 353.87M | 353.87M | 353.87M | 353.87M | 353.18M | 350.19M | 349.21M | 353.41M | 345.35M | 329.05M | 328.66M | 328.18M | 302.03M | 302.03M | 302.03M | 301.90M |
| Weighted Average Shares Outstanding Diluted | 709.39M | 709.39M | 354.61M | 354.60M | 353.87M | 353.87M | 353.87M | 353.87M | 353.41M | 353.41M | 353.41M | 353.41M | 345.36M | 329.05M | 328.66M | 328.18M | 302.03M | 302.03M | 302.03M | 301.90M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $306.39M | $510.91M | $415.15M | $699.33M | $422.16M |
| Short Term Investments | $90.41M | $93.20M | $314.83M | $159.17M | $70.05M |
| Cash and Short Term Investments | $396.80M | $604.11M | $729.98M | $858.50M | $492.22M |
| Net Receivables | $218.38M | $123.40M | $275.77M | $153.34M | $136.88M |
| Inventory | $31.12M | $30.89M | $29.82M | $25.79M | $13.59M |
| Other Current Assets | $35.66M | $144.76M | $123.04M | $63.58M | $62.83M |
| Total Current Assets | $681.96M | $903.16M | $1.07B | $1.10B | $658.84M |
| Property Plant Equipment Net | $823.94M | $806.56M | $650.20M | $484.60M | $337.30M |
| Goodwill | $282.85M | $275.63M | $274.82M | $257.57M | $247.37M |
| Intangible Assets | $26.44M | $15.45M | $23.82M | $30.85M | $98.04M |
| Goodwill and Intangible Assets | $309.30M | $291.09M | $298.64M | $288.42M | $345.41M |
| Long Term Investments | $42.15M | $142.09M | $150.33M | $287.01M | $59.02M |
| Tax Assets | $17.33M | $- | $10.33M | $17.36M | $24.95M |
| Other Non-Current Assets | $37.82M | $109.56M | $74.08M | $56.84M | $37.38M |
| Total Non-Current Assets | $1.23B | $1.35B | $1.18B | $1.13B | $804.05M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.91B | $2.25B | $2.26B | $2.24B | $1.46B |
| Account Payables | $85.79M | $134.32M | $97.28M | $72.60M | $42.55M |
| Short Term Debt | $50.80M | $149.09M | $16.38M | $50.61M | $30.01M |
| Tax Payables | $13.97M | $5.57M | $8.99M | $10.60M | $3.36M |
| Deferred Revenue | $109.81M | $- | $136.67M | $126.78M | $70.65M |
| Other Current Liabilities | $84.21M | $175.60M | $78.39M | $63.93M | $61.89M |
| Total Current Liabilities | $344.58M | $464.57M | $337.71M | $324.52M | $208.46M |
| Long Term Debt | $392.74M | $477.11M | $490.29M | $462.31M | $461.96M |
| Deferred Revenue Non-Current | $187.24M | $- | $206.14M | $34.48M | $26.13M |
| Deferred Tax Liabilities Non-Current | $14.52M | $- | $18.52M | $17.69M | $20.40M |
| Other Non-Current Liabilities | $20.90M | $237.46M | $17.40M | $18.49M | $23.10M |
| Total Non-Current Liabilities | $615.39M | $714.57M | $732.36M | $532.96M | $531.59M |
| Other Liabilities | $- | $-46.59M | $- | $- | $- |
| Total Liabilities | $959.98M | $1.13B | $1.07B | $857.48M | $740.05M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $177.55M | $177.19M | $176.95M | $176.61M | $163.91M |
| Retained Earnings | $-672.37M | $-476.29M | $-392.38M | $-216.42M | $-434.25M |
| Accumulated Other Comprehensive Income Loss | $-7.35M | $-30.64M | $-37.40M | $-12.64M | $-37.52M |
| Other Total Stockholders Equity | $1.45B | $1.45B | $1.44B | $1.43B | $1.03B |
| Total Stockholders Equity | $952.52M | $1.12B | $1.19B | $1.38B | $722.85M |
| Total Equity | $952.52M | $1.12B | $1.19B | $1.38B | $722.85M |
| Total Liabilities and Stockholders Equity | $1.91B | $2.25B | $2.26B | $2.24B | $1.46B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.91B | $2.25B | $2.26B | $2.24B | $1.46B |
| Total Investments | $132.56M | $235.30M | $465.16M | $446.18M | $59.02M |
| Total Debt | $443.54M | $626.20M | $506.67M | $512.92M | $491.96M |
| Net Debt | $137.15M | $115.29M | $91.52M | $-186.41M | $69.80M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $306.39M | $231.30M | $221.88M | $428.31M | $510.91M | $499.37M | $459.75M | $-718.49M | $415.15M | $463.91M | $696.99M | $660.49M | $699.33M | $333.40M | $382.31M | $401.60M | $422.16M | $215.90M | $224.44M | $285.41M |
| Short Term Investments | $90.41M | $147.22M | $76.98M | $81.63M | $93.20M | $119.81M | $173.22M | $1.44B | $314.83M | $364.88M | $193.90M | $194.56M | $159.17M | $93.82M | $77.39M | $68.98M | $70.05M | $42.06M | $51.99M | $35.86M |
| Cash and Short Term Investments | $396.80M | $378.52M | $298.87M | $509.94M | $604.11M | $619.18M | $632.97M | $718.49M | $729.98M | $828.79M | $890.90M | $855.04M | $858.50M | $427.23M | $459.70M | $470.58M | $492.22M | $257.96M | $276.42M | $321.27M |
| Net Receivables | $218.38M | $227.75M | $260.19M | $213.87M | $204.06M | $219.37M | $291.30M | $- | $275.77M | $146.33M | $131.13M | $134.02M | $153.34M | $136.62M | $116.18M | $154.67M | $136.88M | $129.14M | $128.01M | $104.63M |
| Inventory | $31.12M | $35.77M | $37.34M | $31.84M | $30.89M | $31.91M | $32.61M | $- | $29.82M | $30.87M | $29.00M | $26.08M | $25.79M | $22.52M | $17.25M | $15.24M | $13.59M | $11.69M | $10.60M | $10.86M |
| Other Current Assets | $35.66M | $56.05M | $59.11M | $70.49M | $144.76M | $74.55M | $81.69M | $- | $123.04M | $94.95M | $96.46M | $46.37M | $63.58M | $51.60M | $52.03M | $49.94M | $62.83M | $28.40M | $30.56M | $27.86M |
| Total Current Assets | $681.96M | $698.10M | $655.50M | $826.15M | $903.16M | $939.20M | $1.03B | $718.49M | $1.07B | $1.10B | $1.14B | $1.06B | $1.10B | $628.31M | $634.80M | $680.40M | $658.84M | $427.19M | $445.58M | $464.62M |
| Property Plant Equipment Net | $823.94M | $813.80M | $819.73M | $826.90M | $806.56M | $763.90M | $721.14M | $- | $650.20M | $600.50M | $559.53M | $521.36M | $484.60M | $472.82M | $449.47M | $374.93M | $337.30M | $270.29M | $264.26M | $245.70M |
| Goodwill | $282.85M | $- | $- | $- | $275.63M | $- | $277.49M | $- | $274.82M | $278.42M | $259.00M | $257.65M | $257.57M | $253.71M | $252.96M | $254.04M | $247.37M | $247.47M | $249.19M | $252.92M |
| Intangible Assets | $26.44M | $295.87M | $296.12M | $295.12M | $15.45M | $291.06M | $15.12M | $- | $23.82M | $25.74M | $26.98M | $29.16M | $30.85M | $33.23M | $35.81M | $95.69M | $98.04M | $105.80M | $109.13M | $113.23M |
| Goodwill and Intangible Assets | $309.30M | $295.87M | $296.12M | $295.12M | $291.09M | $291.06M | $292.61M | $- | $298.64M | $304.15M | $285.99M | $286.81M | $288.42M | $286.94M | $288.77M | $349.73M | $345.41M | $353.27M | $358.32M | $366.14M |
| Long Term Investments | $42.15M | $123.48M | $129.28M | $135.63M | $142.09M | $151.62M | $160.84M | $- | $150.33M | $189.25M | $217.16M | $236.62M | $287.01M | $303.84M | $175.43M | $108.27M | $59.02M | $52.46M | $53.76M | $46.17M |
| Tax Assets | $17.33M | $36.05M | $29.38M | $21.82M | $60.91M | $10.05M | $11.38M | $- | $10.33M | $16.04M | $18.50M | $16.26M | $17.36M | $24.72M | $26.42M | $25.67M | $24.95M | $25.04M | $31.86M | $33.18M |
| Other Non-Current Assets | $37.82M | $23.50M | $68.88M | $103.04M | $95.23M | $98.69M | $88.80M | $-718.49M | $74.08M | $56.91M | $68.08M | $62.46M | $56.84M | $51.23M | $46.22M | $41.70M | $37.38M | $41.42M | $36.90M | $27.75M |
| Total Non-Current Assets | $1.23B | $1.29B | $1.34B | $1.38B | $1.40B | $1.32B | $1.27B | $-718.49M | $1.18B | $1.17B | $1.15B | $1.12B | $1.13B | $1.14B | $986.31M | $900.31M | $804.05M | $742.49M | $745.09M | $718.94M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.91B | $1.99B | $2.00B | $2.21B | $2.30B | $2.25B | $2.30B | $- | $2.26B | $2.26B | $2.29B | $2.19B | $2.24B | $1.77B | $1.62B | $1.58B | $1.46B | $1.17B | $1.19B | $1.18B |
| Account Payables | $85.79M | $69.89M | $86.94M | $99.14M | $134.32M | $96.77M | $106.04M | $- | $97.28M | $83.97M | $80.89M | $74.74M | $72.60M | $56.72M | $51.36M | $54.88M | $42.55M | $44.14M | $37.47M | $41.79M |
| Short Term Debt | $50.80M | $- | $45.33M | $154.82M | $149.09M | $144.29M | $151.64M | $- | $16.38M | $14.11M | $14.38M | $50.64M | $50.61M | $49.36M | $63.91M | $30.14M | $30.01M | $28.93M | $23.65M | $21.58M |
| Tax Payables | $13.97M | $3.79M | $8.39M | $5.85M | $5.57M | $7.73M | $10.48M | $- | $8.99M | $9.78M | $8.64M | $12.68M | $10.60M | $5.09M | $1.91M | $5.72M | $3.36M | $4.38M | $867.00K | $1.79M |
| Deferred Revenue | $109.81M | $107.40M | $106.27M | $107.17M | $107.86M | $119.32M | $150.43M | $- | $136.67M | $146.97M | $150.12M | $127.38M | $126.78M | $78.67M | $79.12M | $96.78M | $70.65M | $68.02M | $78.14M | $84.10M |
| Other Current Liabilities | $84.21M | $152.54M | $110.55M | $76.06M | $67.75M | $65.94M | $69.52M | $- | $78.39M | $85.98M | $66.51M | $74.18M | $63.93M | $63.94M | $50.65M | $52.08M | $61.89M | $49.41M | $41.36M | $35.77M |
| Total Current Liabilities | $344.58M | $333.62M | $357.48M | $443.05M | $464.57M | $434.05M | $488.11M | $- | $337.71M | $340.80M | $320.56M | $339.62M | $324.52M | $253.78M | $246.95M | $239.61M | $208.46M | $194.88M | $181.49M | $185.04M |
| Long Term Debt | $392.74M | $- | $428.18M | $472.73M | $477.11M | $444.45M | $382.51M | $- | $490.29M | $477.98M | $468.75M | $467.93M | $462.31M | $451.25M | $448.95M | $486.93M | $461.96M | $425.73M | $466.22M | $437.82M |
| Deferred Revenue Non-Current | $187.24M | $208.21M | $127.67M | $150.52M | $155.29M | $199.03M | $219.65M | $- | $206.14M | $179.97M | $192.86M | $32.34M | $34.48M | $28.14M | $30.14M | $17.47M | $26.13M | $33.14M | $24.62M | $28.00M |
| Deferred Tax Liabilities Non-Current | $14.52M | $- | $14.97M | $18.04M | $64.72M | $18.60M | $19.13M | $- | $18.52M | $17.18M | $17.42M | $17.55M | $17.69M | $19.21M | $19.58M | $20.65M | $20.40M | $19.18M | $19.91M | $20.84M |
| Other Non-Current Liabilities | $20.90M | $480.51M | $59.12M | $17.79M | $17.45M | $17.56M | $17.53M | $- | $17.40M | $18.20M | $18.59M | $17.73M | $18.49M | $22.79M | $22.92M | $23.00M | $23.10M | $23.96M | $22.37M | $22.39M |
| Total Non-Current Liabilities | $615.39M | $688.72M | $629.95M | $659.09M | $714.57M | $679.64M | $638.83M | $- | $732.36M | $693.34M | $697.62M | $535.54M | $532.96M | $521.39M | $521.60M | $548.05M | $531.59M | $502.02M | $533.11M | $509.06M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $959.98M | $1.02B | $987.43M | $1.10B | $1.18B | $1.11B | $1.13B | $- | $1.07B | $1.03B | $1.02B | $875.16M | $857.48M | $775.17M | $768.54M | $787.66M | $740.05M | $696.90M | $714.60M | $694.09M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $12.03M | $- | $- | $- | $- | $- | $- | $21.62M | $25.01M | $22.39M | $- | $34.43M | $30.91M | $20.72M |
| Common Stock | $177.55M | $177.55M | $177.55M | $177.55M | $177.19M | $177.19M | $177.19M | $- | $176.95M | $176.95M | $176.95M | $176.95M | $176.61M | $165.11M | $164.61M | $164.56M | $163.91M | $151.90M | $151.45M | $151.24M |
| Retained Earnings | $-672.37M | $-631.53M | $-591.90M | $-496.96M | $-476.29M | $-482.84M | $-448.26M | $- | $-392.38M | $-364.63M | $-317.36M | $-289.63M | $-216.42M | $-186.25M | $-320.69M | $-381.25M | $-434.25M | $-435.39M | $-433.88M | $-429.20M |
| Accumulated Other Comprehensive Income Loss | $-7.35M | $-29.37M | $-6.87M | $-22.99M | $-18.05M | $-0 | $-12.03M | $1.19B | $-37.40M | $-21.35M | $-19.36M | $-9.91M | $-12.64M | $-21.62M | $-25.01M | $-22.39M | $-37.52M | $-34.43M | $-30.91M | $-20.72M |
| Other Total Stockholders Equity | $1.45B | $1.45B | $1.43B | $1.45B | $1.44B | $1.45B | $1.41B | $- | $1.44B | $1.44B | $1.44B | $1.43B | $1.43B | $1.04B | $1.03B | $1.03B | $1.03B | $790.70M | $789.42M | $788.14M |
| Total Stockholders Equity | $952.52M | $968.47M | $1.01B | $1.11B | $1.12B | $1.14B | $1.17B | $1.19B | $1.19B | $1.23B | $1.28B | $1.31B | $1.38B | $992.68M | $852.57M | $793.05M | $722.85M | $472.77M | $476.08M | $489.47M |
| Total Equity | $952.52M | $968.47M | $1.01B | $1.11B | $1.12B | $1.14B | $1.17B | $1.19B | $1.19B | $1.23B | $1.28B | $1.31B | $1.38B | $992.68M | $852.57M | $793.05M | $722.85M | $472.77M | $476.08M | $489.47M |
| Total Liabilities and Stockholders Equity | $1.91B | $1.99B | $2.00B | $2.21B | $2.30B | $2.25B | $2.30B | $1.19B | $2.26B | $2.26B | $2.29B | $2.19B | $2.24B | $1.77B | $1.62B | $1.58B | $1.46B | $1.17B | $1.19B | $1.18B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.91B | $1.99B | $2.00B | $2.21B | $2.30B | $2.25B | $2.30B | $1.19B | $2.26B | $2.26B | $2.29B | $2.19B | $2.24B | $1.77B | $1.62B | $1.58B | $1.46B | $1.17B | $1.19B | $1.18B |
| Total Investments | $132.56M | $270.70M | $206.26M | $217.26M | $235.30M | $271.43M | $334.06M | $1.44B | $465.16M | $554.13M | $411.06M | $236.62M | $446.18M | $303.84M | $175.43M | $108.27M | $59.02M | $52.46M | $53.76M | $46.17M |
| Total Debt | $443.54M | $- | $473.51M | $627.55M | $626.20M | $588.74M | $534.15M | $- | $506.67M | $492.09M | $483.13M | $518.57M | $512.92M | $500.61M | $512.86M | $517.08M | $491.96M | $454.66M | $489.87M | $459.40M |
| Net Debt | $137.15M | $-231.30M | $251.63M | $199.24M | $115.29M | $89.38M | $74.39M | $718.49M | $91.52M | $28.18M | $-213.86M | $-141.92M | $-186.41M | $167.21M | $130.55M | $115.48M | $69.80M | $238.76M | $265.44M | $173.99M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-196.08M | $-83.91M | $-175.66M | $215.51M | $6.25M |
| Depreciation and Amortization | $101.62M | $92.98M | $81.66M | $67.61M | $56.06M |
| Deferred Income Tax | $2.10M | $3.32M | $7.72M | $5.07M | $7.49M |
| Stock Based Compensation | $5.04M | $9.63M | $9.92M | $7.80M | $5.29M |
| Change in Working Capital | $-68.21M | $-9.94M | $119.26M | $-2.28M | $-36.87M |
| Accounts Receivables | $- | $- | $-38.43M | $-48.03M | $-4.18M |
| Inventory | $- | $- | $-4.41M | $-11.65M | $-3.63M |
| Accounts Payables | $- | $- | $24.55M | $31.34M | $2.17M |
| Other Working Capital | $-68.21M | $-9.94M | $137.55M | $26.06M | $-31.23M |
| Other Non Cash Items | $173.75M | $24.37M | $160.20M | $-171.47M | $6.51M |
| Net Cash Provided by Operating Activities | $18.22M | $36.44M | $203.11M | $122.24M | $44.72M |
| Investments in Property Plant and Equipment | $-117.47M | $-213.32M | $-181.35M | $-118.94M | $-99.07M |
| Acquisitions Net | $42.78M | $-20.16M | $-79.69M | $-21.09M | $-33.63M |
| Purchases of Investments | $-29.39M | $-48.39M | $-355.82M | $-123.70M | $-70.93M |
| Sales Maturities of Investments | $35.67M | $260.36M | $205.17M | $27.25M | $54.79M |
| Other Investing Activities | $-2.78M | $8.22M | $-4.13M | $-7.38M | $-6.24M |
| Net Cash Used for Investing Activities | $-71.19M | $-13.29M | $-415.82M | $-243.85M | $-155.09M |
| Debt Repayment | $-152.07M | $84.60M | $-53.11M | $14.77M | $-5.16M |
| Common Stock Issued | $- | $219.00K | $699.00K | $404.32M | $249.97M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-9.35M | $-12.63M | $-5.73M | $-20.66M | $1.59M |
| Net Cash Used Provided by Financing Activities | $-161.42M | $71.96M | $-52.41M | $398.43M | $246.41M |
| Effect of Forex Changes on Cash | $9.87M | $644.00K | $-19.04M | $-66.00K | $9.51M |
| Net Change in Cash | $-204.52M | $95.75M | $-284.17M | $276.75M | $145.55M |
| Cash at End of Period | $306.39M | $510.91M | $415.15M | $699.33M | $422.58M |
| Cash at Beginning of Period | $510.91M | $415.15M | $699.33M | $422.58M | $277.03M |
| Operating Cash Flow | $18.22M | $36.44M | $203.11M | $122.24M | $44.72M |
| Capital Expenditure | $-132.24M | $-216.00M | $-181.35M | $-118.94M | $-99.07M |
| Free Cash Flow | $-114.02M | $-179.56M | $21.75M | $3.29M | $-54.35M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-40.84M | $-39.63M | $-94.93M | $-20.67M | $-16.13M | $-38.95M | $-14.93M | $-13.90M | $-27.20M | $-47.27M | $-27.94M | $-73.24M | $-31.48M | $134.27M | $60.02M | $52.70M | $403.00K | $-1.41M | $-9.82M | $17.08M |
| Depreciation and Amortization | $- | $- | $- | $- | $92.16M | $24.40M | $22.38M | $22.38M | $80.10M | $-37.72M | $37.72M | $- | $65.93M | $-29.08M | $29.08M | $- | $54.25M | $-28.35M | $28.35M | $- |
| Deferred Income Tax | $- | $- | $- | $- | $-4.60M | $- | $- | $- | $7.72M | $- | $- | $- | $5.07M | $- | $- | $- | $7.49M | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $9.63M | $- | $- | $- | $9.92M | $- | $- | $- | $7.80M | $- | $- | $- | $5.29M | $- | $- | $- |
| Change in Working Capital | $-44.45M | $50.51M | $-14.14M | $-60.12M | $15.84M | $10.65M | $-2.12M | $-34.32M | $-24.34M | $-35.00M | $134.92M | $43.69M | $13.78M | $-16.55M | $22.46M | $-21.97M | $5.88M | $6.62M | $-44.39M | $-4.99M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $-38.43M | $- | $- | $- | $-48.03M | $- | $- | $- | $-4.18M | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $-4.41M | $- | $- | $- | $-11.65M | $- | $- | $- | $-3.63M | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $-44.45M | $50.51M | $-14.14M | $-60.12M | $15.84M | $10.65M | $-18.22M | $-18.22M | $18.50M | $-35.00M | $134.92M | $43.69M | $-39.81M | $-16.55M | $22.46M | $-21.97M | $10.63M | $6.62M | $-44.39M | $-4.99M |
| Other Non Cash Items | $159.51M | $31.72M | $58.65M | $33.60M | $23.65M | $24.66M | $10.85M | $48.84M | $-79.72M | $116.02M | $70.01M | $93.17M | $78.03M | $-96.92M | $-43.83M | $-28.27M | $17.65M | $22.55M | $20.10M | $15.04M |
| Net Cash Provided by Operating Activities | $74.22M | $42.60M | $-50.42M | $-47.19M | $18.77M | $20.76M | $-6.20M | $626.00K | $-33.53M | $-3.97M | $176.99M | $63.62M | $60.34M | $20.80M | $38.65M | $2.46M | $23.94M | $27.75M | $-34.10M | $27.13M |
| Investments in Property Plant and Equipment | $-15.20M | $-26.78M | $-39.65M | $-39.17M | $-66.04M | $-45.92M | $-60.93M | $-43.11M | $-24.14M | $-75.84M | $-38.45M | $-42.92M | $-18.76M | $-27.61M | $-36.28M | $-36.30M | $-43.72M | $-26.63M | $-12.37M | $-16.34M |
| Acquisitions Net | $55.40M | $-4.84M | $- | $467.00K | $1.05M | $-6.31M | $-1.36M | $-3.27M | $-32.20M | $11.92M | $-44.28M | $-15.13M | $-2.43M | $-5.06M | $-4.84M | $-8.76M | $-2.52M | $-14.96M | $-11.24M | $-4.90M |
| Purchases of Investments | $-21.39M | $- | $-2.51M | $-13.27M | $-36.44M | $-3.89M | $19.19M | $-38.39M | $-24.31M | $-170.22M | $-74.99M | $-86.30M | $-85.30M | $-18.41M | $-10.50M | $-9.49M | $-34.03M | $-2.79M | $-31.07M | $-3.04M |
| Sales Maturities of Investments | $4.88M | $5.67M | $5.12M | $19.99M | $58.70M | $42.24M | $82.87M | $77.95M | $99.86M | $8.03M | $48.65M | $48.62M | $12.60M | $1.98M | $2.07M | $10.59M | $14.29M | $14.69M | $15.04M | $10.78M |
| Other Investing Activities | $-6.77M | $24.00K | $5.75M | $1.00K | $6.05M | $-1.89M | $-4.58M | $1.00K | $67.24M | $-2.07M | $-2.05M | $-52.81M | $-3.23M | $-1.19M | $-408.00K | $-2.55M | $-6.24M | $-3.07M | $-27.27M | $2.83M |
| Net Cash Used for Investing Activities | $16.92M | $-25.92M | $-31.28M | $-31.98M | $-36.69M | $-15.76M | $33.45M | $-4.65M | $19.21M | $-228.18M | $-111.12M | $-95.73M | $-97.11M | $-50.28M | $-49.95M | $-46.50M | $-72.23M | $-29.70M | $-39.64M | $-13.51M |
| Debt Repayment | $-24.55M | $-5.95M | $-115.43M | $-6.15M | $40.44M | $43.37M | $13.31M | $-3.07M | $2.51M | $-4.65M | $-40.88M | $-5.62M | $2.45M | $-20.11M | $-5.52M | $17.29M | $-9.42M | $-3.11M | $11.30M | $-3.93M |
| Common Stock Issued | $- | $- | $157.00K | $365.00K | $219.00K | $- | $- | $- | $344.00K | $-345.00K | $10.00K | $345.00K | $401.93M | $1.20M | $-646.00K | $646.00K | $248.98M | $448.00K | $221.00K | $326.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-4.78M | $-1.24M | $-3.61M | $277.00K | $-22.55M | $-2.00K | $-3.61M | $-407.00K | $-4.81M | $-1.00K | $345.00K | $- | $1.20M | $-693.00K | $1.39M | $- | $1.59M | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $-29.33M | $-7.18M | $-119.04M | $-5.78M | $30.97M | $43.37M | $13.96M | $-3.48M | $-1.96M | $-4.65M | $-40.53M | $-5.28M | $405.58M | $-19.61M | $-5.47M | $17.93M | $241.15M | $-2.66M | $11.52M | $-3.60M |
| Effect of Forex Changes on Cash | $13.27M | $-81.00K | $-5.68M | $2.36M | $-1.50M | $-8.75M | $5.63M | $5.27M | $-32.48M | $3.72M | $11.17M | $-1.45M | $-2.88M | $184.00K | $-2.50M | $5.13M | $13.83M | $-3.93M | $1.25M | $-1.65M |
| Net Change in Cash | $75.09M | $9.41M | $-206.43M | $-82.60M | $11.54M | $39.61M | $46.83M | $-2.23M | $-48.76M | $-233.08M | $36.50M | $-38.84M | $365.92M | $-48.91M | $-19.29M | $-20.98M | $206.68M | $-8.54M | $-60.97M | $8.38M |
| Cash at End of Period | $306.39M | $231.30M | $221.88M | $428.31M | $510.91M | $499.37M | $459.75M | $412.92M | $415.15M | $463.91M | $696.99M | $660.49M | $699.33M | $333.40M | $382.31M | $401.60M | $422.58M | $215.90M | $224.44M | $285.41M |
| Cash at Beginning of Period | $231.30M | $221.88M | $428.31M | $510.91M | $499.37M | $459.75M | $412.92M | $415.15M | $463.91M | $696.99M | $660.49M | $699.33M | $333.40M | $382.31M | $401.60M | $422.58M | $215.90M | $224.44M | $285.41M | $277.03M |
| Operating Cash Flow | $74.22M | $42.60M | $-52.54M | $-47.19M | $18.77M | $20.76M | $-6.20M | $626.00K | $-33.53M | $-3.97M | $176.99M | $63.62M | $60.34M | $20.80M | $38.65M | $2.46M | $23.94M | $27.75M | $-34.10M | $27.13M |
| Capital Expenditure | $-25.08M | $-28.34M | $-39.65M | $-39.17M | $-66.04M | $-45.92M | $-60.93M | $-43.11M | $-24.14M | $-75.84M | $-38.45M | $-42.92M | $-18.76M | $-27.61M | $-36.28M | $-36.30M | $-43.72M | $-26.63M | $-12.37M | $-16.34M |
| Free Cash Flow | $49.14M | $14.26M | $-90.07M | $-86.37M | $-47.27M | $-25.16M | $-67.13M | $-42.48M | $-57.67M | $-79.81M | $138.54M | $20.70M | $41.58M | $-6.81M | $2.37M | $-33.84M | $-19.79M | $1.12M | $-46.48M | $10.79M |
Evotec SE Dividends
Explore Evotec SE's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
0.14x
Evotec SE Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.2888 | $0.0722 | January 11, 2019 | |||
| $0.1804 | $0.0451 | December 12, 2018 | |||
| $0.1804 | $0.0451 | November 08, 2018 | |||
| $0.1804 | $0.0451 | October 10, 2018 | |||
| $0.1804 | $0.0451 | September 13, 2018 | |||
| $0.1804 | $0.0451 | August 10, 2018 | |||
| $0.1804 | $0.0451 | July 11, 2018 | |||
| $0.1804 | $0.0451 | June 08, 2018 | |||
| $0.1804 | $0.0451 | May 10, 2018 | |||
| $0.1804 | $0.0451 | April 11, 2018 | |||
| $0.1804 | $0.0451 | March 09, 2018 | |||
| $0.1804 | $0.0451 | February 09, 2018 | |||
| $0.1804 | $0.0451 | January 11, 2018 | |||
| $0.1804 | $0.0451 | December 08, 2017 | |||
| $0.1804 | $0.0451 | November 10, 2017 | |||
| $0.1804 | $0.0451 | October 11, 2017 | |||
| $0.1804 | $0.0451 | September 08, 2017 | |||
| $0.1804 | $0.0451 | August 09, 2017 | |||
| $0.1804 | $0.0451 | July 11, 2017 | |||
| $0.2036 | $0.0509 | June 08, 2017 |
Evotec SE News
Read the latest news about Evotec SE, including recent articles, headlines, and updates.
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs Performance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE / ACCESS Newswire / April 24, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced further significant progress of the Company's strategic research collaboration with Bristol Myers Squibb relating to building a high value molecular glue-based pipeline for unmet medical needs. Performance-based and program-based achievements trigger payments of in total US$ 75 m to Evotec.
Evotec SE (EVO) Q4 2024 Earnings Call Transcript
Evotec SE (NASDAQ:EVO ) Q4 2024 Earnings Conference Call April 17, 2025 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Aurélie Dalbiez - Chief People Officer Conference Call Participants Christian Ehmann - Warburg Research Michael Ryskin - Bank of America Charles Weston - RBC Capital Markets Brendan Smith - TD Cowen Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Full-Year Result 2024 Analyst Call. I am Yusuf, the Chorus Call operator.
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence Strong Q4 2024 revenue and EBITDA results in spite of challenging market conditions. Full year guidance met, with liquidity significantly improved Priority Reset on track to deliver annualised recurring gross savings of € 40 m 2025 guidance: group revenues to grow 5 - 10 % (€ 840 - 880 m); 2028 outlook foresees revenue CAGR2024-2028 between 8 - 12% and generation of EBITDA margin above 20 % HAMBURG, GERMANY / ACCESS Newswire / April 17, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process.
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025
HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025. The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process.
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb (NYSE: BMY). The latest scientific achievement in the partnership has triggered a research payment of US$20 m to Evotec, enabling further development of a promising pre-clinical programme in neurodegeneration.
Evotec Announces Change in Management Board
Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire / February 26, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Chief Financial Officer, Laetitia Rouxel, will step down from her role of Chief Financial Officer effective 28 February 2025 and leave the Company effective 31 March 2025 to pursue other opportunities. Laetitia Rouxel joined Evotec in April 2023 as Chief Financial Officer and member of the Management Board of Evotec.
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases
Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy Funding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF).
Evotec: Some Recovery Has Come, But Much More Is Expected
Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside.
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center. LAB eN² is also expanding to include five additional academic institutions: Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai.
Comment on Withdrawn Non-Binding Offer
HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for EUR11.00 per share in cash. The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec.
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. Helen Torley, president and chief executive officer of Halozyme , shared the following statement: "We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees.
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO , Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders.
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
On Thursday, Halozyme Therapeutics, Inc. HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value of 2.0 billion euros (around $2.11 billion).
Comment on Media Report
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec's undisturbed share price on October 15, 2024, the day prior to Triton Partners' initial accumulation of Evotec shares, and a premium of 77% to Evotec's last three-month volume weighted average price on October 15, 2024.
Evotec SE (EVO) Q3 2024 Earnings Call Transcript
Evotec SE (NASDAQ:EVO ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer & Site Head Toulouse Conference Call Participants Charles Weston - RBC Capital Markets Michael Ryskin - Bank of America Christian Ehmann - Warburg Research Benjamin Jackson - Jefferies Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Nine Months 2024 Capital Market Briefing Conference Call. I am Sachin, the Chorus Call Operator.
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships Successful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutions Priority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced its financial results and corporate updates for the third quarter of 2024, highlighting strategic progress across key partnerships and operations.
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners Transaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth drivers New ownership committed to maintaining and growing the business HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) has announced the sale of its chemical API manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, to Monacum Partners GmbH - a Munich based Private Equity firm. This transaction forms part of Evotec's "Priority Reset" initiative launched in April 2024, which aims to foster profitable growth by refining the company's operational footprint and focusing on its primary growth sectors and core competencies.
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process.
Evotec and Bristol Myers Squibb Expand Proteomics Partnership
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a programme-based payment of US$ 50 m to Evotec.
Kia Gwangmyeong EVO Plant Opens to Significantly Expand EV Production
Kia celebrates the completion of Hyundai Motor Group's first dedicated EV manufacturing facility Kia Gwangmyeong EVO Plant, located at Kia Autoland Gwangmyeong, to mass-produce Kia EV3 and EV4 models The new facility to have production capacity of 150,000 units per year Previous internal combustion engine (ICE) vehicle plant transformed to facilitate EV production and accelerate delivery of Kia's strategic sustainable manufacturing and mobility goals Cutting-edge manufacturing initiatives include water-based painting as well as automated processes The EVO Plant to set a new era for Kia's move towards electrification, through production of the brand's high quality EV lineup SEOUL, South Korea, Sept. 26, 2024 /PRNewswire/ -- Kia Corporation has today celebrated the opening of Kia Gwangmyeong EVO Plant, Hyundai Motor Group's (the Group) first dedicated EV manufacturing facility.
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for EVO.